Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening Products

Team Effort Needed To Report On Science, University Of Alberta Study Says
Trust in science is diminishing, according to recent studies, especially in the area of biomedicine, biotech and genetics. University of Alberta researchers Tim Caulfield and Tania Bubela blame it on the complexity of many discoveries and they"re concerned the whole message from the study isn"t getting across to the general public.
generic viagra online
UGA Grad Program Expands To Prepare Teachers To Work With Secondary Students With Autism
An innovative University of Georgia graduate program in special education that has prepared scores of Georgia teachers to work with elementary-age students with autism over the last several years has received a new 4-year, $793,000 federal grant to train teachers to work with similarly challenged secondary-age students.
News of the day
Surfers Take Their Knocks, Doctor Says
Surfing under the influence of drugs or alcohol are two of the prime dangers facing surfing enthusiasts, according to information presented today at the 56th Annual Meeting of the American College of Sports Medicine in Seattle. Other factors include wave height, board length and interactions among surfers.
Medical Devices

2009/039 NICE Guidance Recommends Lenalidomide For Multiple Myeloma

The National Institute for Health and Clinical Excellence (NICE) has published final guidance on the use of lenalidomide for multiple myeloma in people who have received at least one prior therapy. The new NICE guidance recommends lenalidomide in combination with dexamethasone as a treatment option for people with multiple myeloma who have received two or more prior therapies. The cost of the drug beyond 26 cycles (each of 28 days; normally a period of 2 years) will be met by the manufacturer, Celgene. For those patients who have not received two or more prior therapies, but are currently receiving lenalidomide, the independent Appraisal Committee has recommended they have the option to continue treatment until they and their clinician consider it appropriate to stop. Professor Peter Littlejohns, Clinical and Public Health Director at NICE said: "Multiple myeloma is a type of cancer that develops from cells in the bone marrow and there is currently no cure for the disease, only treatments to stop the progress of the condition and help relieve symptoms. It is an uncommon cancer, with less than 4000 new cases per year in the UK. "Following a proposal from the manufacturer of lenalidomide, where they bear the costs of the drug beyond 26 cycles (normally for a period of 2 years), the independent Appraisal Committee was able to recommend lenalidomide as treatment option for multiple myeloma in people who have received two or more prior therapies. The Committee also accepted that lenalidomide fitted NICE"s criteria for allowing its advisory bodies greater flexibility when making recommendations on the use of end of life treatments. "NICE already recommended bortezomib (Velcade) in October 2007 under a risk sharing scheme for patients who are experiencing their first relapse and publication of this new NICE guidance is good news for patients who have already tried other chemotherapy regimens." National Institute for Health and Clinical Excellence


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009